A Phase 3 interventional study of WC3011 Estradiol Vaginal Cream in Vulvovaginal Atrophy, sponsored by Warner Chilcott. Completed at 64 sites in United States. Open to female participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2022-05-09.
Sponsored by Warner Chilcott (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label extension study evaluating the long-term safety and efficacy of WC3011 in non-hysterectomized, healthy, postmenopausal women with vulvovaginal atrophy.
Warner Chilcott is the lead sponsor of 58 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
First submitted before Warner Chilcott became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Developed any of the following during Study-PR04409.3 or has begun taking hormone therapy other than WC3011:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
WC3011 estradiol vaginal cream 3 times a week for up to 40 weeks.
Drug: WC3011 Estradiol Vaginal Cream
WC3011 estradiol vaginal cream, 3 times a week for 40 weeks.
Number of Participants With Endometrial Biopsy Results at Final Visit
The endometrial biopsy results was categorized as: normal results categorized as atrophic/inactive or proliferative, unsatisfactory with endometrial thickness ≤4 mm and missing biopsy with endometrial thickness ≤4 mm; abnormal results categorized as polyp, hyperplasia, and carcinoma; unknown result categorized as unsatisfactory with endometrial thickness \>4 mm, missing biopsy with endometrial thickness \>4 mm, unsatisfactory without transvaginal ultrasonography (TVU) result and missing biopsy without TVU result. The duration of estradiol exposure was combination of studies PR-04409.3 and PR-04509.
Time frame: Final Visit (Day closest to Day 281)
Change From Baseline in Participants Self-Assessment of the Symptoms of Vulvovaginal Atrophy (VVA) at Each Post-baseline Timepoints
Self-Assessment of the symptoms of VVA was evaluated for vaginal dryness, vaginal Itching, dysuria, and dyspareunia by a questionnaire. Questionnaire consisted of 5 questions scaled from 0 to 3 level of intensity, where 0-none indicated symptom not present; 1-mild indicated symptom is present but may be intermittent; does not interfere with your activities or lifestyle; 2-moderate indicated symptom is present, aware of the symptom but activities and lifestyle are only occasionally affected; 3-severe indicated usually aware and bothered by the symptom and have modified your activities and/or lifestyle due to the symptom. Higher score indicated most bothersome symptoms. A negative change from Baseline indicates improvement. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.
Time frame: Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Weeks 4, 8, 16, 24, 32, 40 and Final Visit (Day closest to Day 281)
Change From Baseline in Vaginal Cytology: Percentage of Superficial Vaginal Cells
Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.
Time frame: Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Week 40 and Final Visit (Day closest to Day 281)
Change From Baseline in Vaginal Cytology: Percentage of Parabasal Vaginal Cells
Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.
Time frame: Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Week 40 and Final Visit (Day closest to Day 281)
Change From Baseline in Vaginal pH
Vaginal pH was obtained at final visit of the study. The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.
Time frame: Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Week 40 and Final Visit (Day closest to Day 281)
Change From Baseline as Per Investigator's Assessment of Each of the Signs of VVA
Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to the signs of VVA: atrophy, pallor, vaginal dryness, friability, and petechiae scored on a 4-point scale where: 0=none, 1=mild, 2=moderate, or 3= severe. The negative change from Baseline indicates improvement. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.
Time frame: Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Week 40 and Final Visit (Day closest to Day 281)
Number of Participants With At Least One Treatment Emergent Adverse Event (TEAE)
An adverse event is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal (investigational) product, whether or not related to medicinal (investigational) product. TEAE are defined as those AEs with onset date on or after the first dose date of study drug in Study PR-04509, or adverse events that worsen after the first dose date of study drug in Study PR-04509.
Time frame: Up to Week 40
| Milestone | Previous WC3011 Estradiol Vaginal Cream (2 Times/Week) | Previous Vehicle (2 Times/Week) | Previous WC3011 Estradiol Vaginal Cream (3 Times/Week) | Previous Vehicle (3 Times/Week) |
|---|---|---|---|---|
| Started | 101 | 56 | 100 | 52 |
| All-participants-treated population | 101 | 56 | 99 | 52 |
| Completed | 84 | 48 | 80 | 42 |
| Not completed | 17 | 8 | 20 | 10 |
| Withdrew: Adverse event | 7 | 0 | 5 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 | 2 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 | 2 | 1 |
| Withdrew: Withdrew consent | 6 | 5 | 8 | 5 |
| Withdrew: Reason not specified | 1 | 2 | 3 | 3 |
The endometrial biopsy results was categorized as: normal results categorized as atrophic/inactive or proliferative, unsatisfactory with endometrial thickness ≤4 mm and missing biopsy with endometrial thickness ≤4 mm; abnormal results categorized as polyp, hyperplasia, and carcinoma; unknown result categorized as unsatisfactory with endometrial thickness \>4 mm, missing biopsy with endometrial thickness \>4 mm, unsatisfactory without transvaginal ultrasonography (TVU) result and missing biopsy without TVU result. The duration of estradiol exposure was combination of studies PR-04409.3 and PR-04509.
| Participants | WC3011 Estradiol Vaginal Cream: Less Than 92 Days | WC3011 Estradiol Vaginal Cream: 92-182 Days | WC3011 Estradiol Vaginal Cream: 183-273 Days | WC3011 Estradiol Vaginal Cream: More Than 273 Days |
|---|---|---|---|---|
| Normal Biopsy: Atrophic | 3 | 10 | 7 | 166 |
| Normal Biopsy: Proliferative | 0 | 1 | 1 | 3 |
| Normal Biopsy: Unsatisfactory With Endometrial Thickness ≤4 mm | 0 | 3 | 4 | 48 |
| Normal Biopsy: Missing Biopsy With Endometrial Thickness ≤4 mm | 1 | 1 | 1 | 21 |
| Abnormal Biopsy: Polyp | 0 | 0 | 0 | 1 |
| Unknown: Unsatisfactory With Endometrial Thickness >4 mm | 0 | 1 | 0 | 6 |
| Unknown: Missing Biopsy With Endometrial Thickness >4 mm | 0 | 0 | 0 | 1 |
| Unknown: Unsatisfactory Without TVU Result | 0 | 2 | 0 | 3 |
| Unknown: Missing Biopsy Without TVU Result | 3 | 9 | 6 | 6 |
Self-Assessment of the symptoms of VVA was evaluated for vaginal dryness, vaginal Itching, dysuria, and dyspareunia by a questionnaire. Questionnaire consisted of 5 questions scaled from 0 to 3 level of intensity, where 0-none indicated symptom not present; 1-mild indicated symptom is present but may be intermittent; does not interfere with your activities or lifestyle; 2-moderate indicated symptom is present, aware of the symptom but activities and lifestyle are only occasionally affected; 3-severe indicated usually aware and bothered by the symptom and have modified your activities and/or lifestyle due to the symptom. Higher score indicated most bothersome symptoms. A negative change from Baseline indicates improvement. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.
| score on a scale | Previous WC3011 Estradiol Vaginal Cream (2 Times/Week) | Previous Vehicle (2 Times/Week) | Previous WC3011 Estradiol Vaginal Cream (3 Times/Week) | Previous Vehicle (3 Times/Week) |
|---|---|---|---|---|
| Vaginal Dryness-Baseline | 1.2 ± 0.92 | 1.5 ± 0.91 | 1.2 ± 0.87 | 1.5 ± 1.06 |
| Vaginal Dryness-Change From Baseline to Week 4 | -0.3 ± 0.71 | -0.3 ± 0.79 | -0.3 ± 0.62 | -0.2 ± 0.61 |
| Vaginal Dryness-Change From Baseline to Week 8 | -0.4 ± 0.81 | -0.5 ± 0.80 | -0.4 ± 0.65 | -0.4 ± 0.64 |
| Vaginal Dryness-Change From Baseline to Week 16 | -0.5 ± 0.75 | -0.6 ± 0.91 | -0.4 ± 0.72 | -0.3 ± 0.80 |
| Vaginal Dryness-Change From Baseline to Week 24 | -0.6 ± 0.80 | -0.6 ± 0.78 | -0.3 ± 0.72 | -0.3 ± 0.85 |
| Vaginal Dryness-Change From Baseline to Week 32 | -0.5 ± 0.88 | -0.7 ± 0.75 | -0.3 ± 0.68 | -0.4 ± 0.95 |
| Vaginal Dryness-Change From Baseline to Week 40 | -0.5 ± 0.87 | -0.6 ± 0.86 | -0.4 ± 0.78 | -0.5 ± 0.94 |
| Vaginal Dryness-Change From Baseline to Final Visit | -0.4 ± 0.89 | -0.6 ± 0.89 | -0.3 ± 0.76 | -0.5 ± 0.90 |
| Vaginal Itching-Baseline | 0.6 ± 0.73 | 0.5 ± 0.71 | 0.5 ± 0.70 | 0.5 ± 0.67 |
| Vaginal Itching-Change From Baseline to Week 4 | -0.3 ± 0.63 | -0.0 ± 0.66 | -0.2 ± 0.60 | -0.0 ± 0.80 |
| Vaginal Itching-Change From Baseline to Week 8 | -0.2 ± 0.74 | -0.1 ± 0.64 | -0.3 ± 0.63 | 0.0 ± 0.68 |
| Vaginal Itching-Change From Baseline to Week 16 | -0.3 ± 0.77 | -0.0 ± 0.69 | -0.1 ± 0.70 | 0.1 ± 0.47 |
| Vaginal Itching-Change From Baseline to Week 24 | -0.3 ± 0.74 | -0.2 ± 0.59 | -0.2 ± 0.72 | 0.0 ± 0.58 |
| Vaginal Itching-Change From Baseline to Week 32 | -0.2 ± 0.69 | -0.2 ± 0.64 | -0.2 ± 0.64 | -0.1 ± 0.59 |
| Vaginal Itching-Change From Baseline to Week 40 | -0.3 ± 0.80 | -0.3 ± 0.66 | -0.3 ± 0.71 | -0.0 ± 0.47 |
| Vaginal Itching-Change From Baseline to Final Visit | -0.3 ± 0.78 | -0.3 ± 0.67 | -0.3 ± 0.71 | -0.0 ± 0.64 |
| Dysuria-Baseline | 0.1 ± 0.42 | 0.2 ± 0.49 | 0.1 ± 0.33 | 0.1 ± 0.43 |
| Dysuria-Change From Baseline to Week 4 | -0.1 ± 0.37 | -0.0 ± 0.50 | -0.0 ± 0.25 | -0.1 ± 0.33 |
| Dysuria-Change From Baseline to Week 8 | -0.1 ± 0.41 | -0.0 ± 0.44 | 0.0 ± 0.35 | -0.0 ± 0.20 |
| Dysuria-Change From Baseline to Week 16 | -0.1 ± 0.41 | -0.1 ± 0.51 | -0.0 ± 0.28 | 0.0 ± 0.14 |
| Dysuria-Change From Baseline to Week 24 | -0.1 ± 0.29 | -0.2 ± 0.47 | -0.0 ± 0.28 | 0.0 ± 0.21 |
| Dysuria-Change From Baseline to Week 32 | -0.1 ± 0.33 | -0.1 ± 0.54 | -0.0 ± 0.29 | 0.0 ± 0.22 |
| Dysuria-Change From Baseline to Week 40 | -0.1 ± 0.30 | -0.1 ± 0.41 | 0.0 ± 0.37 | 0.0 ± 0.27 |
| Dysuria-Change From Baseline to Final Visit | -0.1 ± 0.32 | -0.1 ± 0.49 | 0.0 ± 0.40 | 0.0 ± 0.28 |
| Dyspareunia-Baseline | 1.3 ± 1.14 | 1.3 ± 1.14 | 1.2 ± 1.08 | 1.6 ± 1.24 |
| Dyspareunia-Change From Baseline to Week 4 | -0.3 ± 0.69 | -0.5 ± 0.69 | -0.2 ± 0.66 | -0.5 ± 0.80 |
| Dyspareunia-Change From Baseline to Week 8 | -0.3 ± 0.82 | -0.5 ± 0.77 | -0.3 ± 0.63 | -0.5 ± 1.13 |
| Dyspareunia-Change From Baseline to Week 16 | -0.5 ± 0.93 | -0.6 ± 0.85 | -0.4 ± 0.83 | -0.5 ± 0.88 |
| Dyspareunia-Change From Baseline to Week 24 | -0.6 ± 0.96 | -0.6 ± 0.85 | -0.4 ± 0.86 | -0.6 ± 1.01 |
| Dyspareunia-Change From Baseline to Week 32 | -0.5 ± 0.95 | -0.7 ± 0.94 | -0.4 ± 0.78 | -0.6 ± 0.93 |
| Dyspareunia-Change From Baseline to Week 40 | -0.6 ± 0.99 | -0.5 ± 0.82 | -0.3 ± 0.72 | -0.7 ± 1.06 |
| Dyspareunia-Change From Baseline to Final Visit | -0.5 ± 0.94 | -0.6 ± 0.91 | -0.3 ± 0.72 | -0.6 ± 1.15 |
Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.
| percentage of superficial cells | Previous WC3011 Estradiol Vaginal Cream (2 Times/Week) | Previous Vehicle (2 Times/Week) | Previous WC3011 Estradiol Vaginal Cream (3 Times/Week) | Previous Vehicle (3 Times/Week) |
|---|---|---|---|---|
| Baseline | 10.4 ± 11.73 | 4.0 ± 7.72 | 16.1 ± 18.77 | 3.1 ± 7.99 |
| Change From Baseline to Week 40 | 12.8 ± 21.26 | 17.6 ± 18.21 | 0.5 ± 20.69 | 13.9 ± 24.56 |
| Change From Baseline to Final Visit | 11.0 ± 20.98 | 15.9 ± 17.59 | -0.2 ± 21.79 | 13.0 ± 23.02 |
Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.
| percentage of parabasal cells | Previous WC3011 Estradiol Vaginal Cream (2 Times/Week) | Previous Vehicle (2 Times/Week) | Previous WC3011 Estradiol Vaginal Cream (3 Times/Week) | Previous Vehicle (3 Times/Week) |
|---|---|---|---|---|
| Baseline | 9.7 ± 24.34 | 42.2 ± 41.46 | 12.0 ± 29.28 | 34.2 ± 38.74 |
| Change From Baseline to Week 40 | 0.0 ± 20.78 | -42.2 ± 42.00 | -1.5 ± 33.28 | -21.2 ± 36.83 |
| Change From Baseline to Final Visit | -0.4 ± 22.30 | -36.3 ± 43.18 | 1.2 ± 34.67 | -24.0 ± 36.80 |
Vaginal pH was obtained at final visit of the study. The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.
| score on a scale | Previous WC3011 Estradiol Vaginal Cream (2 Times/Week) | Previous Vehicle (2 Times/Week) | Previous WC3011 Estradiol Vaginal Cream (3 Times/Week) | Previous Vehicle (3 Times/Week) |
|---|---|---|---|---|
| Baseline | 5.5 ± 0.81 | 6.2 ± 1.06 | 5.4 ± 0.80 | 6.1 ± 0.99 |
| Change From Baseline to Week 40 | -0.3 ± 0.97 | -1.0 ± 1.24 | -0.2 ± 1.04 | -0.8 ± 0.95 |
| Change From Baseline to Final Visit | -0.2 ± 1.04 | -1.0 ± 1.19 | -0.1 ± 1.08 | -1.0 ± 1.04 |
Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to the signs of VVA: atrophy, pallor, vaginal dryness, friability, and petechiae scored on a 4-point scale where: 0=none, 1=mild, 2=moderate, or 3= severe. The negative change from Baseline indicates improvement. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.
| score on a scale | Previous WC3011 Estradiol Vaginal Cream (2 Times/Week) | Previous Vehicle (2 Times/Week) | Previous WC3011 Estradiol Vaginal Cream (3 Times/Week) | Previous Vehicle (3 Times/Week) |
|---|---|---|---|---|
| Atrophy-Baseline | 1.1 ± 0.70 | 1.5 ± 0.76 | 1.1 ± 0.69 | 1.4 ± 0.80 |
| Atrophy-Change From Baseline to Week 40 | -0.3 ± 0.79 | -0.7 ± 0.82 | -0.3 ± 0.81 | -0.5 ± 0.77 |
| Atrophy-Change From Baseline to Final Visit | -0.2 ± 0.82 | -0.6 ± 0.80 | -0.2 ± 0.84 | -0.6 ± 0.84 |
| Pallor-Baseline | 1.1 ± 0.78 | 1.5 ± 0.83 | 1.0 ± 0.74 | 1.3 ± 0.77 |
| Pallor-Change From Baseline to Week 40 | -0.4 ± 0.81 | -0.8 ± 1.00 | -0.3 ± 0.79 | -0.5 ± 0.77 |
| Pallor-Change From Baseline to Final Visit | -0.4 ± 0.83 | -0.6 ± 0.99 | -0.2 ± 0.82 | -0.6 ± 0.77 |
| Dryness-Baseline | 1.0 ± 0.81 | 1.4 ± 0.89 | 1.0 ± 0.78 | 1.1 ± 1.01 |
| Dryness-Change From Baseline to Week 40 | -0.4 ± 0.73 | -1.0 ± 0.92 | -0.4 ± 0.87 | -0.4 ± 0.86 |
| Dryness-Change From Baseline to Final Visit | -0.4 ± 0.75 | -0.8 ± 0.97 | -0.3 ± 0.92 | -0.5 ± 0.94 |
| Friability-Baseline | 0.4 ± 0.67 | 0.6 ± 0.82 | 0.3 ± 0.59 | 0.5 ± 0.75 |
| Friability-Change From Baseline to Week 40 | -0.2 ± 0.57 | -0.5 ± 0.85 | -0.2 ± 0.67 | -0.2 ± 0.69 |
| Friability-Change From Baseline to Final Visit | -0.2 ± 0.55 | -0.4 ± 0.88 | -0.1 ± 0.73 | -0.3 ± 0.73 |
| Petechiae-Baseline | 0.3 ± 0.63 | 0.6 ± 0.80 | 0.2 ± 0.59 | 0.4 ± 0.75 |
| Petechiae-Change From Baseline at Week 40 | -0.1 ± 0.45 | -0.5 ± 0.80 | -0.1 ± 0.56 | -0.1 ± 0.65 |
| Petechiae-Change From Baseline to Final Visit | -0.1 ± 0.44 | -0.5 ± 0.79 | -0.1 ± 0.54 | -0.2 ± 0.63 |
An adverse event is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal (investigational) product, whether or not related to medicinal (investigational) product. TEAE are defined as those AEs with onset date on or after the first dose date of study drug in Study PR-04509, or adverse events that worsen after the first dose date of study drug in Study PR-04509.
| Participants | WC3011 Estradiol Vaginal Cream |
|---|---|
| Number of Participants With At Least One Treatment Emergent Adverse Event (TEAE) | 195 |
Collected over Up to Week 40. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| WC3011 Estradiol Vaginal Cream | 0/308 (0%) | 8/308 (2.6%) | 50/308 (16.2%) |
| Event | WC3011 Estradiol Vaginal Cream |
|---|---|
| CholelithiasisHepatobiliary disorders | 1/308 |
| Femoral artery occlusionVascular disorders | 1/308 |
| DysarthriaNervous system disorders | 1/308 |
| Confusional statePsychiatric disorders | 1/308 |
| VertigoEar and labyrinth disorders | 1/308 |
| AppendicitisInfections and infestations | 1/308 |
| Atrial fibrillationCardiac disorders | 1/308 |
| PalpitationsCardiac disorders | 1/308 |
| Transient ischaemic attackNervous system disorders | 1/308 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/308 |
| Event | WC3011 Estradiol Vaginal Cream |
|---|---|
| Vulvovaginal Mycotic InfectionInfections and infestations | 23/308 |
| Upper Respiratory Tract InfectionInfections and infestations | 17/308 |
| SinusitisInfections and infestations | 16/308 |
All participants who received at least 1 dose of study drug in Study PR-04509.
| Age, Continuous(years) | WC3011 Estradiol Vaginal Cream |
|---|---|
| Mean | 59.0 ± 5.54 |
| Sex: Female, Male(Participants) | WC3011 Estradiol Vaginal Cream |
|---|---|
| Female | 308 |
| Male | 0 |
Ran from Oct 2011 to primary completion in Dec 2012, 13 months.
Results were first posted in May 2022, 9 years 5 months after primary completion. A results delay was requested in Feb 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol